+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Non-alcoholic fatty liver disease comorbid with major depressive disorder: The pathological features and poor therapeutic efficacy



Non-alcoholic fatty liver disease comorbid with major depressive disorder: The pathological features and poor therapeutic efficacy



Journal of Gastroenterology and Hepatology 30(6): 1009-1014



Major depressive disorder (MDD) is an important public health problem, and it is often comorbid with many chronic diseases. The purpose of this study was to identify the clinical features of non-alcoholic fatty liver disease (NAFLD) patients comorbid with MDD and to investigate the influence of MDD on the effect of treatment in patients with NAFLD. A total of 258 patients with biopsy-proven NAFLD were included. MDD was diagnosed according to the criteria of the Diagnostic and Statistical Manual of Mental Disorders, 4th edition, text revision. The patients were followed up for 48 weeks under standard care for NAFLD, which consisted mainly of lifestyle modification. There were 32 patients comorbid with MDD. They were characterized by more severe histological steatosis and higher NAFLD activity score, and also significantly higher levels of serum aminotransferase, γ-glutamyl transpeptidase and ferritin, than age-and-sex-matched NAFLD patients without MDD. Moreover, NAFLD patients with MDD showed poor response to the standard care for NAFLD, in body weight loss and in other parameters. Particularly, NAFLD patients with unstable MDD (not in full/partial remission) showed severe resistance to the treatment. This is the first study to demonstrate the clinical features and response to therapy of NAFLD patients comorbid with MDD. The comorbid state of MDD was associated with more severe histological liver steatosis and worse treatment outcomes in patients with NAFLD. Further investigations are required to develop new lifestyle modification programs that enable NAFLD patients with MDD to achieve the treatment goal.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 058414222

Download citation: RISBibTeXText

PMID: 25619308

DOI: 10.1111/jgh.12897


Related references

Abnormal function of monoamine oxidase-A in comorbid major depressive disorder and cardiovascular disease: pathophysiological and therapeutic implications (review). Molecular Medicine Reports 6(5): 915-922, 2013

Membrane Omega-3 Fatty Acid Deficiency as a Preventable Risk Factor for Comorbid Coronary Heart Disease in Major Depressive Disorder. Cardiovascular Psychiatry and Neurology 2009: 1-13, 2009

Membrane omega-3 Fatty Acid deficiency as a preventable risk factor for comorbid coronary heart disease in major depressive disorder. Cardiovascular Psychiatry and Neurology 2009: 362795, 2009

Efficacy of venlafaxine extended release in patients with major depressive disorder and comorbid generalized anxiety disorder. Journal of Clinical Psychiatry 62(7): 523-529, 2001

Efficacy and Long-Term Clinical Outcome of Comorbid Posttraumatic Stress Disorder and Major Depressive Disorder After Electroconvulsive Therapy. Depression and Anxiety 33(7): 640-647, 2017

Major depressive disorder and comorbid cardiac disease: is there a depressive subtype with greater cardiovascular morbidity? Results from the STAR*D study. Psychosomatics 48(5): 418-425, 2007

Clinical and pathological features of sarcopenia-related indices in patients with non-alcoholic fatty liver disease. Hepatology Research 2019, 2019

Angiopoietin-2 promotes pathological angiogenesis and is a novel therapeutic target in murine non-alcoholic fatty liver disease. Hepatology 2018, 2018

Omega-3 polyunsaturated fatty acid (PUFA) status in major depressive disorder with comorbid anxiety disorders. Journal of Clinical Psychiatry 74(7): 732-738, 2013

Refinement of a clinicopathological typing system for non-alcoholic fatty liver disease Clinical, biochemical, and pathological features in 98 patients with NAFLD. Hepatology 38(4 Suppl 1): 505A, 2003

What clinical and symptom features and comorbid disorders characterize outpatients with anxious major depressive disorder: a replication and extension. Canadian Journal of Psychiatry. Revue Canadienne de Psychiatrie 51(13): 823-835, 2007

Prescribing patterns of psychotropic medications and clinical features in patients with major depressive disorder with and without comorbid dysthymia in China. Asia-Pacific Psychiatry 9(1), 2016

Omega-3 Polyunsaturated Fatty Acids (n-3 PUFAs) in Cardiovascular Diseases Comorbid Major Depressive Disorder (MDD)- Results from a Randomized Controlled Trial. Brain, Behavior, and Immunity 2019, 2019

Impact of medical comorbid disease on antidepressant treatment of major depressive disorder. Current Psychiatry Reports 6(3): 193-201, 2004

Patient-reported outcomes of quality of life, functioning, and depressive symptom severity in major depressive disorder comorbid with panic disorder before and after SSRI treatment in the star*d trial. Depression and Anxiety 31(8): 707-716, 2015